Detailed answers about LIHELI PHARMACEUTICAL UK LIMITED, including incorporation, status, business activity, and accounts information.
When was LIHELI PHARMACEUTICAL UK LIMITED founded?
LIHELI PHARMACEUTICAL UK LIMITED was officially incorporated on 13 March 2025 and is registered under company number 16313798. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is LIHELI PHARMACEUTICAL UK LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of LIHELI PHARMACEUTICAL UK LIMITED?
LIHELI PHARMACEUTICAL UK LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does LIHELI PHARMACEUTICAL UK LIMITED do?
LIHELI PHARMACEUTICAL UK LIMITED operates in the following sectors: 46450 - Wholesale of perfume and cosmetics, 46900 - Non-specialised wholesale trade, 47750 - Retail sale of cosmetic and toilet articles in specialised stores, 47910 - Retail sale via mail order houses or via Internet. These SIC codes provide insight into the company's business activities and industry focus.
What is LIHELI PHARMACEUTICAL UK LIMITED's registered address?
The registered office address of LIHELI PHARMACEUTICAL UK LIMITED is OFFICE SUITE 29A, 3/F.,, 23 WHARF STREET, LONDON, ENGLAND, SE8 3GG. This is the official address filed with Companies House for legal and statutory correspondence.
Is LIHELI PHARMACEUTICAL UK LIMITED financially stable?
Financial accounts for LIHELI PHARMACEUTICAL UK LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.